Survival
The median follow-up time for all patients was 30.2 months. For all patients, IC+CCRT group showed no prolonged LRPFS (median: 21 vs.15.3 months, P =0.825; Figure 1A), DMFS (median: 21.37 vs. 13.6 months,P =0.839; Figure 1B), PFS (median: 20.17 vs.11.38 months,P =0.906; Figure 1C) and OS (median: 27.1 vs.18.03 months,P =0.846; Figure 1D) compared to IC+RT alone group. However, for IC responders, IC+CCRT comparing to IC+RT alone significantly prolonged the LRPFS (median: 39.3 vs. 15.13 months, P =0.033; Figure 2A), DMFS (median: 27.87 vs.13.6 months, P =0.044; Figure 2B), PFS (median:27.87 vs.11.37 months, P =0.048; Figure 2C) and OS (median:39.33 vs.18.03 months, P =0.027; Figure 2D). Notably, IC+CCRT failed to benefit for survival compared to IC+RT alone in IC non-responders (Supplementary Figure 2A-D).
Further, multivariate analysis for the IC responders showed that IC+CCRT was benefit factor for LRPFS (HR: 0.391, 95% CI: 0.16-0.957,P =0.04), and OS (HR:0.361, 95% CI:0.141-0.922, P =0.033) (see Table 3).